Platelet GPIIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies.

نویسندگان

  • V S Mahadevan
  • D McCarty
  • A A J Adgey
چکیده

Early and complete restoration of myocardial blood flow is the therapeutic goal for treatment of patients with acute myocardial infarction (MI). After fibrinolytic therapy patients who fail to achieve Thrombolysis in Myocardial Infarction (TIMI) grade 3 epicardial blood flow are at high risk of death and congestive heart failure. With currently available thrombolytic therapies less than two-thirds of patients have TIMI grade 3 flow in the infarct related artery 90 min after initiation of thrombolytic therapy. Thus in patients who fail to reperfuse following thrombolytic therapy, there is a need for rescue therapies. To identify candidates for rescue therapy, clinicians use information from the ECG and patient history. While ST resolution is a highly accurate predictor of infarct artery patency, restoration of normal epicardial flow is not sufficient to ensure adequate myocardial perfusion. Percutaneous coronary intervention (PCI) has been shown to be successful in restoring vessel patency in up to 90% of patients undergoing a rescue procedure. In addition in the ADMIRAL study, early use of a platelet glycoprotein IIb/IIIa inhibitor (GPIIb/IIIa), abciximab, started prior to primary stenting for acute MI, has shown greater initial TIMI 3 flow before stenting with greater success rate of the stenting procedure and lower combined end point of death, reinfarction or urgent target vessel revascularisation at 30 days. Furthermore at 6 months improvement in coronary patency and left ventricular function was maintained. Abciximab, as part of rescue therapy with PCI, has been shown to improve clinical outcomes and left ventricular function. In this issue Ronner et al. have presented a single centre retrospective study of patients who were admitted or transferred with a myocardial infarction and underwent rescue therapy within 24 h for failed thrombolysis. Since treatment strategies were not randomised they have emphasised bleeding rates rather than mortality. Rescue therapy for failed thrombolysis included PCI, further lytic therapy and GPIIb/IIIa inhibitors often in combination. Of the 154 with primary admission to the Thoraxcenter and who had thrombolysis for acute

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis.

BACKGROUND AND PURPOSE Intraarterial and intravenous thrombolysis are often ineffective for the treatment of acute ischemic stroke and are associated with a significant risk of intracranial hemorrhage (ICH). Multimodal rescue therapy combining mechanical disruption and platelet GPIIb/IIIa receptor antagonists may improve recanalization. METHODS Patients who did not recanalize with thrombolysi...

متن کامل

Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks.

The optimal reperfusion strategy in elderly patients with ST-segment elevation myocardial infarction (STEMI) remains a topic of debate. This lack of consensus stems from the exclusion or under-representation of the elderly in clinical trials. This review evaluates the available literature pertaining to reperfusion therapy for the treatment of STEMI in the elderly. We identified all published st...

متن کامل

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.

Although thrombolytic therapy has been a major advance in the treatment of acute ST-segment elevation myocardial infarction (MI), new thrombolytic agents have been unable to improve early reperfusion. Because aspirin has been shown to be a very effective adjunctive agent in patients with acute MI, it has been hypothesized that the use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors c...

متن کامل

Platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.

Several reports have recently opened a new therapeutic window for the use of platelet glycoprotein (GP) IIb/IIIa receptor blockade as an adjunct to thrombolytic therapy in acute myocardial infarction. Because of the different protocols and the different agents that were used, as well as the relatively small number of patients included in these studies, one cannot draw any definitive conclusions...

متن کامل

Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor.

Platelets are implicated in a variety of serious vaso-occlusive and thromboembolic disorders that together constitute one of the most common causes of death throughout the world. Platelet aggregation and subsequent thrombosis at the site of an injured atherosclerotic plaque are important causative factors in the pathogenesis of unstable angina, acute myocardial infarction, reocclusion after suc...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • European heart journal

دوره 23 19  شماره 

صفحات  -

تاریخ انتشار 2002